Why the study?
Intravenous thrombolysis is not recommended for acute ischemic stroke patients with warfarin-associated hypocoagulability, and monotherapy reversal is unable to rapidly normalize coagulation, creating a challenge for timely revascularization.
This case demonstrates the feasibility of administering intravenous thrombolysis with rt-PA after rapid reversal of warfarin anticoagulation in a patient with acute ischemic stroke.
Answers are grounded in this paper and cite their sources.
May support rt-PA after warfarin reversal in select stroke cases; leaves open need for prospective safety data.
It is essential for acute ischemic stroke (AIS) patients to receive timely revascularization. However, intravenous thrombolysis (IVT) is not recommended for AIS patients with warfarin associated hypocoagulability. Meanwhile, monotherapy of coagulation factors or vitamin K is unable to reverse anticoagulation of warfarin in emergency. Thus, developing an effective IVT strategy poses a challenging task for these fragile population. Herein, an 82-year-old male, on regular administration with warfarin because of nonvalvular atrial fibrillation (NVAF), suffered from AIS and had an elevated international normalized ratio value of 1.72 and prolonged prothrombin time of 18.2 s at stroke onset. For normalizing INR, combination of 4 factor prothrombin complex concentrate, fresh frozen plasma and vitamin K1 were administrated. Finally, the patient successfully received recombinant tissue plasminogen activator (rt-PA), with an obviously neurological improvement. This case shows a feasible role of IVT therapy with rt-PA after reversal of coagulation regarding AIS patients with warfarin-related hypocoagulability.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: